Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis

Journal of Crohn's and Colitis

Volumn 7, Issue 11, 2013, Pages 916-922

  Wine, Eytan ^a   Mack, David R ^b   Hyams, Jeffrey ^c   Otley, Anthony R ^d   Markowitz, James ^e   Crandall, Wallace V ^f   Leleiko, Neal ^g   Muise, Aleixo M ^h   Griffiths, Anne M ^h   Turner, Dan ⁱ  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c Division of Pediatric Infectious Diseases   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g HASBRO CHILDREN'S HOSPITAL   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Disease marker; Inflammatory bowel diseases; Methylprednisolone; Response to treatment

Indexed keywords

CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD; STEROID THERAPY; TH17 CELL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ACUTE SEVERE ULCERATIVE COLITIS; ASC; C-REACTIVE PROTEIN; CRP; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; ESR; GLUCOCORTOCOID RECEPTOR; GR; IBD; IFN; IL; INFLAMMATORY BOWEL DISEASES; INTERFERON; INTERLEUKIN; INTERQUARTILE RANGE; INTRAVENOUS CORTICOSTEROIDS; IQR; IVCS; METHYLPREDNISOLONE; ODDS RATIO; OR; PEDIATRIC UC ACTIVITY INDEX; PGA; PHYSICIAN GLOBAL ASSESSMENT; PUCAI; RESPONSE TO TREATMENT; T(H); T-HELPER; TNF; TUMOR NECROSIS FACTOR; UC; ULCERATIVE COLITIS;

ACUTE DISEASE; ADOLESCENT; ADRENAL CORTEX HORMONES; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLITIS, ULCERATIVE; CYTOKINES; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884821333     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.12.012     Document Type: Article

References (43)

1. Turner D., Walsh C.M., Benchimol E.I., Mann E.H., Thomas K.E., Chow C., et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008, 57:331-338.
2. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 1041-1048.
3. Turner D., Travis S.P., Griffiths A.M., Ruemmele F.M., Levine A., Benchimol E.I., et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011, 106:574-588.
4. Turner D., Walsh C.M., Steinhart A.H., Griffiths A.M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5:103-110.
5. Sylvester F.A., Turner D., Draghi A., Uuosoe K., McLernon R., Koproske K., et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel Dis 2011, 17:1726-1730.
6. Kabakchiev B., Turner D., Hyams J., Mack D., Leleiko N., Crandall W., et al. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010, 5.
7. Turner D., Kolho K.L., Mack D.R., Raivio T., Leleiko N., Crandall W., et al. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflamm Bowel Dis 2010, 16:469-473.
8. Turner D., Leach S.T., Mack D., Uusoue K., McLernon R., Hyams J., et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010, 59:1207-1212.
9. Michail S., Durbin M., Turner D., Griffiths A.M., Mack D.R., Hyams J., et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis 2012, 18:1799-1808.
10. Turner D., Mack D., Leleiko N., Walters T.D., Uusoue K., Leach S.T., et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010, 138:2282-2291.
11. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
12. Chikanza I.C., Kozaci D., Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J Endocrinol 2003, 179:301-310.
13. Nishimoto N., Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006, 2:619-626.
14. Mudter J., Neurath M.F. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007, 13:1016-1023.
15. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
16. Sventoraityte J., Zvirbliene A., Kiudelis G., Zalinkevicius R., Praskevicius A., Kupcinskas L., et al. Immune system alterations in patients with inflammatory bowel disease during remission. Medicina (Kaunas) 2008, 44:27-33.
17. Travis S., Satsangi J., Lemann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011, 60:3-9.
18. Turner D., Otley A.R., Mack D., Hyams J., de Bruijne J., Uusoue K., et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007, 133:423-432.
19. Seo M., Okada M., Yao T., Okabe N., Maeda K., Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification. Am J Gastroenterol 1995, 90:1759-1763.
20. Lindgren S.C., Flood L.M., Kilander A.F., Lofberg R., Persson T.B., Sjodahl R.I. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998, 10:831-835.
21. Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S., et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012, 10:391-9.
22. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999, 34:66-74.
23. Raddatz D., Bockemuhl M., Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005, 17:547-557.
24. Balding J., Livingstone W.J., Conroy J., Mynett-Johnson L., Weir D.G., Mahmud N., et al. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm 2004, 13:181-187.
25. Tsampalieros A., Griffiths A.M., Barrowman N., Mack D.R. Use of C-reactive protein in children with newly diagnosed inflammatory bowel disease. J Pediatr 2011, 159:340-342.
26. Strandberg K., Palmberg L., Larsson K. Effect of budesonide and formoterol on IL-6 and IL-8 release from primary bronchial epithelial cells. J Asthma 2008, 45:201-203.
27. Quante T., Ng Y.C., Ramsay E.E., Henness S., Allen J.C., Parmentier J., et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 2008, 39:208-217.
28. Tripathi G., Jafar T., Mandal K., Mahdi A.A., Awasthi S., Sharma R.K., et al. Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome?. Indian J Med Sci 2008, 62:383-391.
29. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
30. Lowenberg M., Verhaar A.P., Bilderbeek J., Marle J., Buttgereit F., Peppelenbosch M.P., et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006, 7:1023-1029.
31. Harr M.W., Rong Y., Bootman M.D., Roderick H.L., Distelhorst C.W. Glucocorticoid-mediated inhibition of Lck modulates the pattern of T cell receptor-induced calcium signals by down-regulating inositol 1,4,5-trisphosphate receptors. J Biol Chem 2009, 284:31860-31871.
32. Hausherr A., Tavares R., Schaffer M., Obermeier A., Miksch C., Mitina O., et al. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases. Oncogene 2007, 26:4987-4998.
33. Smolinska M.J., Page T.H., Urbaniak A.M., Mutch B.E., Horwood N.J. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. J Immunol 2011, 187:6043-6051.
34. Irusen E., Matthews J.G., Takahashi A., Barnes P.J., Chung K.F., Adcock I.M. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002, 109:649-657.
35. Webster J.C., Oakley R.H., Jewell C.M., Cidlowski J.A. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 2001, 98:6865-6870.
36. Franchimont D., Martens H., Hagelstein M.T., Louis E., Dewe W., Chrousos G.P., et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999, 84:2834-2839.
37. Hawrylowicz C., Richards D., Loke T.K., Corrigan C., Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol 2002, 109:369-370.
38. Kobayashi T., Okamoto S., Hisamatsu T., Kamada N., Chinen H., Saito R., et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008, 57:1682-1689.
39. Iwanami K., Matsumoto I., Tanaka-Watanabe Y., Inoue A., Mihara M., Ohsugi Y., et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008, 58:754-763.
40. Ruddy M.J., Wong G.C., Liu X.K., Yamamoto H., Kasayama S., Kirkwood K.L., et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004, 279:2559-2567.
41. van den Berg A., Kuiper M., Snoek M., Timens W., Postma D.S., Jansen H.M., et al. Interleukin-17 induces hyperresponsive interleukin-8 and interleukin-6 production to tumor necrosis factor-alpha in structural lung cells. Am J Respir Cell Mol Biol 2005, 33:97-104.
42. Levine A., Griffiths A., Markowitz J., Wilson D.C., Turner D., Russell R.K., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011, 17:1314-1321.
43. Turner D., Otley A.R., Mack D., de Bruijne J., Uusoue K., Walter T., et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): A prospective multicenter study. Gastroenterology 2007, 133:423-432.